Acute kidney injury and acute kidney disease in high-dose cisplatin-treated head and neck cancer.
AKD, acute kidney disease
AKI, acute kidney injury
cancer
cisplatin
head and neck
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
02
2023
accepted:
10
05
2023
medline:
26
6
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
epublish
Résumé
In locally advanced head and neck squamous cell carcinoma (LA-SCCHN) at least 200mg/m One hundred and nine consecutive patients affected by LA-SCCHN and treated with at least a cumulative dosage of 200 mg/m AKI was reported in 12.8% of patients, 50% of whom were stage 1 (KDIGO criteria), while 25.7% of the cohort developed AKD. Patients with baseline estimated Glomerular Filtration Rate (eGFR) < 90 ml/min showed a higher incidence of AKD (36.2% vs 17.7%). Hypertension, baseline eGFR, and therapy with Renin-angiotensin-aldosterone system inhibitors proved to be significant factors associated with both AKI and AKD. AKI and AKD are not rare complications of high-dose cisplatin, but an appropriate prevention strategy and accurate monitoring of patients during treatment could lead to a reduction of the burden of these conditions.
Sections du résumé
Background
UNASSIGNED
In locally advanced head and neck squamous cell carcinoma (LA-SCCHN) at least 200mg/m
Methods
UNASSIGNED
One hundred and nine consecutive patients affected by LA-SCCHN and treated with at least a cumulative dosage of 200 mg/m
Results
UNASSIGNED
AKI was reported in 12.8% of patients, 50% of whom were stage 1 (KDIGO criteria), while 25.7% of the cohort developed AKD. Patients with baseline estimated Glomerular Filtration Rate (eGFR) < 90 ml/min showed a higher incidence of AKD (36.2% vs 17.7%). Hypertension, baseline eGFR, and therapy with Renin-angiotensin-aldosterone system inhibitors proved to be significant factors associated with both AKI and AKD.
Conclusion
UNASSIGNED
AKI and AKD are not rare complications of high-dose cisplatin, but an appropriate prevention strategy and accurate monitoring of patients during treatment could lead to a reduction of the burden of these conditions.
Identifiants
pubmed: 37361572
doi: 10.3389/fonc.2023.1173578
pmc: PMC10289148
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1173578Informations de copyright
Copyright © 2023 Trevisani, Di Marco, Quattrini, Lepori, Floris, Valsecchi, Giordano, Dell’Oca, Cardellini, Cinque and Mirabile.
Déclaration de conflit d'intérêts
Author AC was employed by the company Biorek srl. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMC Pharmacol Toxicol. 2020 Mar 2;21(1):19
pubmed: 32122396
Clin Exp Nephrol. 2009 Dec;13(6):578-84
pubmed: 19629622
Ann Pharmacother. 2014 Apr 28;48(7):863-869
pubmed: 24778426
Kidney Int. 2021 Sep;100(3):516-526
pubmed: 34252450
BMC Cancer. 2019 Nov 8;19(1):1066
pubmed: 31703649
Crit Care. 2007;11(2):R31
pubmed: 17331245
Asian Pac J Cancer Prev. 2015;16(3):1117-22
pubmed: 25735341
Contrib Nephrol. 2011;174:89-97
pubmed: 21921613
Int J Gen Med. 2021 Dec 31;14:10527-10539
pubmed: 35002308
Cancers (Basel). 2020 Jun 26;12(6):
pubmed: 32604773
Am J Clin Oncol. 2018 May;41(5):432-440
pubmed: 27281266
J Clin Oncol. 2018 Mar 1;36(7):682-688
pubmed: 29320311
Support Care Cancer. 2021 Feb;29(2):877-887
pubmed: 32524284
Anticancer Drugs. 2015 Mar;26(3):343-9
pubmed: 25486599
Br J Radiol. 2021 Feb 01;94(1118):20200717
pubmed: 33180666
J Otolaryngol Head Neck Surg. 2018 Feb 02;47(1):10
pubmed: 29394952
Asian Pac J Cancer Prev. 2015;16(16):7331-5
pubmed: 26514533
Br J Cancer. 2003 Apr 22;88(8):1199-206
pubmed: 12698184
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Anticancer Drugs. 2006 Feb;17(2):207-15
pubmed: 16428940
Nat Rev Nephrol. 2016 Sep;12(9):511-2
pubmed: 27374917
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1037-44
pubmed: 20638185
Toxins (Basel). 2010 Nov;2(11):2490-518
pubmed: 22069563
J Oncol Pharm Pract. 2010 Sep;16(3):167-71
pubmed: 19759050
Oncologist. 2017 May;22(5):609-619
pubmed: 28438887
Head Neck. 2016 Apr;38 Suppl 1:E1575-81
pubmed: 26614010
Phytomedicine. 2013 Mar 15;20(5):453-60
pubmed: 23353054
Nat Rev Cancer. 2007 Aug;7(8):573-84
pubmed: 17625587
Head Neck. 2009 Dec;31(12):1600-9
pubmed: 19455705
Kidney Int. 2008 May;73(9):994-1007
pubmed: 18272962
ESMO Open. 2022 Feb;7(1):100351
pubmed: 34953401
Crit Care. 2004 Aug;8(4):R204-12
pubmed: 15312219
PLoS One. 2015 Nov 10;10(11):e0142225
pubmed: 26556481
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Rev Nephrol. 2017 Apr;13(4):241-257
pubmed: 28239173